[ad_1]
An Australian randomized controlled trial of vitamin D supplements, led by the QIMR Berghofer Medical Research Institute, found that they did not protect most people against colds, flu and other acute respiratory infections.
The trial, which is the largest of its kind to study the relationship between vitamin D and respiratory infection to date, however, found that supplements may slightly shorten the duration of infection and help lessen the severity of the infection. these diseases.
The results of the study were published this week in the scientific journal The Lancet Diabetes and Endocrinology.
Researchers analyzed self-reported health data from 16,000 Australians aged 60 to 84, who participated in the D-Health trial led by the QIMR Berghofer Medical Research Institute.
Principal investigator and head of QIMR Berghofer’s Cancer Etiology and Prevention Group, Professor Rachel Neale, said participants who received vitamin D supplements reported having symptoms of colds and flu for a long time. slightly less time than participants who did not take it. They also had severe symptoms for less time and needed less medication to manage their symptoms.
Professor Neale said the trial results are timely as people around the world try to figure out how to best improve their immunity to the Covid-19 pandemic.
“The D-Health trial was completed before the start of the Covid-19 pandemic and therefore does not provide specific answers on this matter. vitamin D supplement, especially in deficient people.
(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)
Dear reader,
Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and that have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times stemming from Covid-19, we continue to remain committed to keeping you informed and up to date with credible news, authoritative opinions and cutting-edge commentary on relevant current issues.
However, we have a demand.
As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with higher quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscribing to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.
Support quality journalism and subscribe to Business Standard.
Digital editor
[ad_2]
Source link
